Featured Research

from universities, journals, and other organizations

Early tumor response from stereotactic radiosurgery predicts outcome

Date:
January 27, 2014
Source:
University of North Carolina School of Medicine
Summary:
The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research.

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina School of Medicine.

Related Articles


The study of 52 patients with metastatic brain legions, published in the January issue of the journal Neurosurgery, found that the tumors whose sizes decreased significantly after treatment with stereotactic radiosurgery (SRS) did not resume growth or require additional treatment. The research, conducted by a team led by Matthew G. Ewend, MD, chair of the UNC Department of Neurosurgery and member of the UNC Lineberger Comprehensive Cancer Center, could reduce the need to continually monitor patients who respond well to SRS.

"We measured the volume of the tumors over time to see if we could predict, based on what happened in the beginning, what would happen long term. What we found was that tumors that did not shrink in the beginning were more likely later to be correlated to a patient having a neurological problem or needing steroids," said Dr. Ewend. "If they did shrink, they were more likely to stay under control long term."

The advent of SRS systems allows physicians to target tumors with precise, high-dose beams of radiation. While the technique is in widespread use, current practice requires repeated check-ups to determine its effectiveness. The results of this study indicate that this monitoring may only be necessary for patients who do not respond favorably within the first six to twelve weeks after SRS treatment.

"You could take fewer MRIs or CAT scans afterwards if you got a good response, because we know they would not fail. We need less imaging with less worry for patients," said Dr. Ewend.

Between 20 and 40 percent of adults with cancer develop brain tumors, which metastasize from cancers elsewhere in the body. The number of brain tumors treated by physicians has increased, as better treatments for the cancers that spawn them increase patient survival. Because of the systemic nature of these cancers, the survival implications of positive early response depend largely on how patients respond to therapy for their initial cancer.

"This is not in a vacuum. Even if you control the brain disease, they can still die of their other disease. With better control of the brain disease, the patients have a better chance of living longer, but it will take both improvements in systemic therapy and brain therapy," said Dr. Ewend.

The UNC study included patients with lung, breast, melanoma and renal cell cancers. It builds on prior research that indicated a similar response in patients with clear cell renal cancer. Dr. Ewend said that future research will need to increase the number of patients to reinforce the results and determine what factors influence positive early response. One possibility for future research is to determine the genetic factors behind tumor response, which will allow researchers to develop a genetic test to help predict a patient's outcome.

"We could eventually predict for individual patients before we treat them what the likelihood is that they would respond," said Dr. Ewend.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Suzanne R. Sharpton, Eric K. Oermann, Dominic T. Moore, Eric Schreiber, Riane Hoffman, David E. Morris, Matthew G. Ewend. The Volumetric Response of Brain Metastases After Stereotactic Radiosurgery and Its Post-treatment Implications. Neurosurgery, 2014; 74 (1): 9 DOI: 10.1227/NEU.0000000000000190

Cite This Page:

University of North Carolina School of Medicine. "Early tumor response from stereotactic radiosurgery predicts outcome." ScienceDaily. ScienceDaily, 27 January 2014. <www.sciencedaily.com/releases/2014/01/140127100945.htm>.
University of North Carolina School of Medicine. (2014, January 27). Early tumor response from stereotactic radiosurgery predicts outcome. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/01/140127100945.htm
University of North Carolina School of Medicine. "Early tumor response from stereotactic radiosurgery predicts outcome." ScienceDaily. www.sciencedaily.com/releases/2014/01/140127100945.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins